A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation
Open accessThe DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation. METHODS: In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once daily, for 12 weeks. The primary efficacy end point was the proportion of patients having three or more spontaneous, complete bowel movements per week, averaged over 12 weeks. Secondary efficacy end points were derived from daily diaries and validated questionnaires completed by patients. Adverse events, clinical laboratory values, and cardiovascular effects were monitored. RESULTS: Efficacy was analyzed in 620 patients. The proportion of patients with three or more spontaneous, complete bowel movements per week was 30.9% of those receiving 2 mg of prucalopride and 28.4% of those receiving 4 mg of prucalopride, as compared with 12.0% in the placebo group (P<0.001 for both comparisons). Over 12 weeks, 47.3% of patients receiving 2 mg of prucalopride and 46.6% of those receiving 4 mg of prucalopride had an increase in the number of spontaneous, complete bowel movements of one or more per week, on average, as compared with 25.8% in the placebo group (P<0.001 for both comparisons). All other secondary efficacy end points, including patients' satisfaction with their bowel function and treatment and their perception of the severity of their constipation symptoms, were significantly improved with the use of 2 or 4 mg of prucalopride as compared with placebo, at week 12. The most frequent treatment-related adverse events were headache and abdominal pain. There were no significant cardiovascular effects of treatment. CONCLUSIONS: Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation. Larger and longer trials are required to further assess the risks and benefits of the use of prucalopride for chronic constipation. (ClinicalTrials.gov number, NCT00483886 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Five 12-week randomized double-blinded placebo-controlled trials evaluated the use of prucalopride (2 mg daily) for the management of CIC. 75-79”
Citations
Cites
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90005-6 · Cited by 4,982
(1994) · Medical Entomology and Zoology · Cited by 4,156
Epidemiology of Constipation in North America: A Systematic Review
Higgins, P. D., & Johanson, J. F. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04114.x · Cited by 1,080
Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults
Straus, S. M. J. M., Kors, J. A., De Bruin, M. L., van der Hooft, C. S., Hofman, A., Heeringa, J., Deckers, J. W., Kingma, J. H., Sturkenboom, M. C. J. M., Stricker, B. H. C., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.067 · Cited by 833
Lembo, A., & Camilleri, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020995 · Cited by 692
Self-citationChronic constipation: a survey of the patient perspective
JOHANSON, J. F., & KRALSTEIN, J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03238.x · Cited by 617
Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire
Marquis, P., De La Loge, C., Dubois, D., McDermott, A., & Chassany, O. (2005) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520510012208 · Cited by 584
Stewart, W. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00701-7 · Cited by 492
Psychometric Validation of a Constipation Symptom Assessment Questionnaire
L. Frank, L. K. (1999) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655299750025327 · Cited by 458
The Health-Related Quality of Life and Economic Burden of Constipation
Dennison, C., Prasad, M., Lloyd, A., Bhattacharyya, S. K., Dhawan, R., & Coyne, K. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523050-00006 · Cited by 396
Research works printed but not linked: 3
- 10.1111/j.1572-0241.1999.01642.x · doi:10.1111/j.1572-0241.1999.01642.x · Paper page
- 10.1111/j.1572-0241.2002.05843.x · doi:10.1111/j.1572-0241.2002.05843.x · Paper page
- Schiller LR, 2004, Rev Gastroenterol Disord, 4, S43
Cited by
American Gastroenterological Association Technical Review on Constipation
Bharucha, A. E., Pemberton, J. H., & Locke, G. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.10.028 · Cited by 909
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 645
The brain-gut axis in abdominal pain syndromes.
Mayer, E. A., & Tillisch, K. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-012309-103958 · Cited by 511
“Compounds targeting colonic 5-HT4 receptors (tegaserod, prucalopride), which are able to accelerate colonic transit, have been found to be effective in patients with IBS and constipation, even though tegaserod (76, 77) has been withdrawn from the market due to side effects, and prucalopride is only available outside t…”
BackgroundCamilleri, M., Ford, A. C., Mawe, G. M., Dinning, P. G., Rao, S. S., Chey, W. D., Simrén, M., Lembo, A., Young-Fadok, T. M., & Chang, L. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.95 · Cited by 411
Self-citationFord, A. C., & Suares, N. C. (2011) · Gut · doi:10.1136/gut.2010.227132 · Cited by 378
“Three trials were at low risk of bias.(35) 36 38 Rescue laxatives were allowed if there was no bowel movement for 3 or more consecutive days in six of the trials, and in the remaining trial this issue was unclear.”
BackgroundTack, J., van Outryve, M., Beyens, G., Kerstens, R., & Vandeplassche, L. (2009) · Gut · doi:10.1136/gut.2008.162404 · Cited by 347
Self-citationQUIGLEY, E. M. M., VANDEPLASSCHE, L., KERSTENS, R., & AUSMA, J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03884.x · Cited by 344
Self-citationManagement of faecal incontinence and constipation in adults with central neurological diseases
Coggrave, M., Norton, C., & Cody, J. D. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002115.pub5 · Cited by 306
Chronic Constipation in the Elderly
Gallegos-Orozco, J. F., Foxx-Orenstein, A. E., Sterler, S. M., & Stoa, J. M. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.349 · Cited by 297
“Recent randomized controlled trials have demonstrated prucaloprides's efficacy for treating chronic constipation (”
BackgroundDiagnosis and treatment of chronic constipation - a European perspective
Tack, J., Müller-Lissner, S., Stanghellini, V., Boeckxstaens, G., Kamm, M. A., Simren, M., Galmiche, J.-P., & Fried, M. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01709.x · Cited by 304
Chronic Constipation: An Evidence-Based Review
Leung, L., Riutta, T., Kotecha, J., & Rosser, W. (2011) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2011.04.100272 · Cited by 300
“157 Clinically, it sig-440 nificantly improved bowel movements and other reported symptoms in patients with chronic constipation, 130 especially in severe cases, 131–134 with no significant cardiovascular adverse events.”
BackgroundTack, J., Camilleri, M., Chang, L., Chey, W. D., Galligan, J. J., Lacy, B. E., Müller‐Lissner, S., Quigley, E. M. M., Schuurkes, J., De Maeyer, J. H., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05011.x · Cited by 286
Self-citationRole of serotonin in gastrointestinal motility and irritable bowel syndrome
Sikander, A., Rana, S. V., & Prasad, K. K. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.01.028 · Cited by 279
“Prucalopride, a selective 5-HT4 receptor agonist, safely and effectively increases bowel movement frequency in adults with chronic constipation, according to a clinical trial [116].”
BackgroundChronic Constipation in the Elderly
Bouras, E. P., & Tangalos, E. G. (2009) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.06.001 · Cited by 275
Epidemiology and management of chronic constipation in elderly patients
Bouras, E., & Vazquez-Roque, M. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s54304 · Cited by 229
“Prucalopride, a 5-hydroxytryptamine receptor 4 agent similar to tegaserod, accelerates colonic transit in patients with constipation, and therapeutic trials have demonstrated efficacy for severe constipation.(88,89) Prucalopride for 4 weeks in elderly nursing home residents was safe and well tolerated, with no adverse…”
Acupuncture for Chronic Severe Functional Constipation: A Randomized Trial
Liu, Z., Yan, S., Wu, J., He, L., Li, N., Dong, G., Fang, J., Fu, W., Fu, L., Sun, J., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-3118 · Cited by 241
“Because 3 or more CSBMs per week indicates normalization of bowel function (4, 19), our results show that EA may normalize bowel function in some patients.”
BackgroundMethodResultInfluentialSerotonin and GI clinical disorders
Spiller, R. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.016 · Cited by 234
Bharucha, A. E., & Wald, A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.031 · Cited by 238
Efficacy of Linaclotide for Patients With Chronic Constipation
Lembo, A. J., Kurtz, C. B., MacDougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., Jeglinski, B. I., & Johnston, J. M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.050 · Cited by 234
Layer, P., Andresen, V., Pehl, C., Allescher, H., Bischoff, S., Claßen, M., Enck, P., Frieling, T., Haag, S., Holtmann, G., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0029-1245976 · Cited by 230
Johnston, J. M., Kurtz, C. B., MacDougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., O'Dea, C., Baird, M., & Lembo, A. J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.041 · Cited by 229
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Sacral nerve stimulation for faecal incontinence and constipation in adults
Thaha, M. A., Abukar, A. A., Thin, N. N., Ramsanahie, A., & Knowles, C. H. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004464.pub3 · Cited by 213
Wong, R. K., Palsson, O. S., Turner, M. J., Levy, R. L., Feld, A. D., von Korff, M., & Whitehead, W. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.200 · Cited by 204
Update on the management of constipation in the elderly: new treatment options
Rao, S., & Go (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s8100 · Cited by 202
Bove, A. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i14.1555 · Cited by 188
Chang, L., Chey, W. D., Imdad, A., Almario, C. V., Bharucha, A. E., Diem, S., Greer, K. B., Hanson, B., Harris, L. A., Ko, C., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.214 · Cited by 185
Crosstalk at the mucosal border: importance of the gut microenvironment in IBS
Öhman, L., Törnblom, H., & Simrén, M. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.200 · Cited by 181
Serotonin in the gastrointestinal tract
Camilleri, M. (2009) · Current Opinion in Endocrinology, Diabetes and Obesity · doi:10.1097/med.0b013e32831e9c8e · Cited by 167
Self-citationNakajima, A., Seki, M., Taniguchi, S., Ohta, A., Gillberg, P.-G., Mattsson, J. P., & Camilleri, M. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30123-7 · Cited by 169
Self-citationNelson, A. D., Camilleri, M., Chirapongsathorn, S., Vijayvargiya, P., Valentin, N., Shin, A., Erwin, P. J., Wang, Z., & Murad, M. H. (2017) · Gut · doi:10.1136/gutjnl-2016-311835 · Cited by 158
Self-citationIrritable bowel syndrome: the clinical approach
Adriani, A., Ribaldone, D. G., Astegiano, M., Durazzo, M., Saracco, G. M., & Pellicano, R. (2018) · Panminerva Medica · doi:10.23736/s0031-0808.18.03541-3 · Cited by 182
Bove, A. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i36.4994 · Cited by 166
Fichna, J., & Storr, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00127 · Cited by 164
“A number of novel 5-HT4 agonists have recently been obtained as potential treatments for patients with IBS-C and appear to be safer than earlier generation agents in these classes (Camilleri et al., 2008; Manini et al., 2010).”
BackgroundA review of laxative therapies for treatment of chronic constipation in older adults
Fleming, V. H., & Wade, W. E. (2010) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/s1543-5946(10)80003-0 · Cited by 151
Shin, A., Camilleri, M., Kolar, G. J., Erwin, P. J., West, C. P., & Murad, M. H. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12571 · Cited by 148
Self-citationEfficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis
Luthra, P., Camilleri, M., Burr, N. E., Quigley, E. M. M., Black, C. J., & Ford, A. C. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30246-8 · Cited by 146
Self-citationmanabe, N., wong, B. S., camilleri, M., burton, D., mckinzie, S., & zinsmeister, A. R. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01442.x · Cited by 142
Self-citationMearin, F., Ciriza, C., Mínguez, M., Rey, E., Mascort, J. J., Peña, E., Cañones, P., & Júdez, J. (2016) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2016.4389/2016 · Cited by 166
Shi, X., Hu, Y., Zhang, B., Li, W., Chen, J. D., & Liu, F. (2021) · JCI Insight · doi:10.1172/jci.insight.150052 · Cited by 142
“The complete spontaneous bowel movement was defined as the bowel movement that occurred without use of any medication or other methods to assist defecation in the previous 24 hours and with a feeling of complete evacuation (87).”
Müller-Lissner, S. A., Rykx, A., Kerstens, R., & Vandeplassche, L. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01533.x · Cited by 137
Self-citationSloots, C., Rykx, A., Cools, M., Kerstens, R., & Pauw, M. D. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1229-y · Cited by 131
Self-citationCamilleri, M., Beyens, G., Kerstens, R., Robinson, P., & Vandeplassche, L. M. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01398.x · Cited by 133
Self-citationProkinetics and fundic relaxants in upper functional GI disorders
Tack, J. F. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.09.009 · Cited by 142
Dinning, P. G., Hunt, L., Patton, V. E., Zhang, T. G., Szczesniak, M. M., Gebski, V., Jones, M., Stewart, P., Lubowski, D. Z., & Cook, I. J. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2015.101 · Cited by 129
Manini, M. L., Camilleri, M., Goldberg, M., Sweetser, S. R., McKinzie, S., Burton, D. B., Wong, S., Kitt, M. M., Li, Y., & Zinsmeister, A. R. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01378.x · Cited by 127
Self-citationChronic constipation: A critical review
Basilisco, G., & Coletta, M. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.03.016 · Cited by 122
“A third definition used in clinical trials is a modified version of the Rome criteria in which abnormal bowel frequency (<3 bowel movements/week) is the necessary condition for inclusion [15–19].”
MethodNeuroimmunophysiology of the gut: advances and emerging concepts focusing on the epithelium
Sharkey, K. A., Beck, P. L., & McKay, D. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0051-4 · Cited by 125
Knowles, C. H., Thin, N. N., Gill, K., Bhan, C., Grimmer, K., Lunniss, P. J., Williams, N. S., & Scott, S. M. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318247d49f · Cited by 115
New perspectives in the diagnosis and management of enteric neuropathies
Knowles, C. H., Lindberg, G., Panza, E., & GIORGIO, R. D. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.18 · Cited by 119
Treatment of Chronic Constipation: Current Pharmacologic Approaches and Future Directions
Tack, J. F., & Müller-Lissner, S. A. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.12.006 · Cited by 119
Singh, R., Zogg, H., Ghoshal, U. C., & Ro, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.808195 · Cited by 122
S2k-Leitlinie Chronische Obstipation: Definition, Pathophysiologie, Diagnostik und Therapie
Andresen, V., Enck, P., Frieling, T., Herold, A., Ilgenstein, P., Jesse, N., Karaus, M., Kasparek, M., Keller, J., Kuhlbusch-Zicklam, R., et al. (2013) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0033-1335808 · Cited by 139
Emmanuel, A. V., Kamm, M. A., Roy, A. J., Kerstens, R., & Vandeplassche, L. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04907.x · Cited by 111
“A recent multi-centre randomised placebo-controlled study has shown that the drug improves bowel function and symptom burden in severe chronic constipation.(12) The drug is well tolerated, with no significant increase in the number adverse effects compared with placebo.”
BackgroundSelf-citationPrucalopride Is No More Effective Than Placebo for Children With Functional Constipation
Mugie, S. M., Korczowski, B., Bódi, P., Green, A., Kerstens, R., Ausma, J., Ruth, M., Levine, A., & Benninga, M. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.09.005 · Cited by 112
“It is unclear why there is a discrepancy in the placebo response between children and adults.(14,18) Behaviour modification, including toilet training and positive parental reinforcement, may be significant factors in explaining the high placebo response rate in children.”
BackgroundSelf-citationKe, M., Zou, D., Yuan, Y., Li, Y., Lin, L., Hao, J., Hou, X., & Kim, H. J. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01983.x · Cited by 107
Yiannakou, Y., Piessevaux, H., Bouchoucha, M., Schiefke, I., Filip, R., Gabalec, L., Dina, I., Stephenson, D., Kerstens, R., Etherson, K., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.115 · Cited by 104
Self-citationManabe, N., Wong, B. S., & Camilleri, M. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.482927 · Cited by 101
“Furthermore, three pivotal Phase III trials have been conducted evaluating the efficacy of prucalopride in patients with chronic constipation, most of whom had been dissatisfied with treatment efficacy of laxatives they were receiving (Table 3) [58-60].”
BackgroundSelf-citationDiabetes Mellitus and the Colon
Piper, M. S., & Saad, R. J. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0151-1 · Cited by 110
Shin, J. E., Jung, H., Lee, T. H., Jo, Y., Lee, H., Song, K. H., Hong, S. N., Lim, H. C., Lee, S. J., Chung, S. S., et al. (2016) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15185 · Cited by 111
Bharucha, A. E., Low, P. A., Camilleri, M., Veil, E. B., Burton, D. D., Kudva, Y. C., Shah, P., Gehrking, T. L., & Zinsmeister, A. R. (2012) · Gut · doi:10.1136/gutjnl-2012-302483 · Cited by 104
“8 CSBM for 4 mg).(34) Similarly to previous studies, patients had a spectrum of complications of DM, type and severity of autonomic dysfunctions, and disturbances of GI and colonic transit.”
MethodSelf-citationCamilleri, M., Outryve, M. J. V., Beyens, G., Kerstens, R., Robinson, P., & Vandeplassche, L. M. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04455.x · Cited by 94
Self-citationManagement of chronic constipation in adults
Krogh, K., Chiarioni, G., & Whitehead, W. E. (2016) · United European Gastroenterology Journal · doi:10.1177/2050640616663439 · Cited by 101
“In randomized placebo-controlled, clinical trials, prucalopride reduced colorectal transit times and alleviated symptoms in patients with idiopathic CC.(29) Linaclotide and lubiprostone enhance secretion from the gut wall and thereby reduce colorectal transit time and symptoms.”
BackgroundInfluentialBowel Dysfunction in Spinal Cord Injury
Qi, Z., Middleton, J. W., & Malcolm, A. (2018) · Current Gastroenterology Reports · doi:10.1007/s11894-018-0655-4 · Cited by 96
Elobixibat and its potential role in chronic idiopathic constipation
Acosta, A., & Camilleri, M. (2014) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x14528269 · Cited by 91
Self-citationCamilleri, M., Piessevaux, H. H., Yiannakou, Y., Tack, J. F., Kerstens, R., Quigley, E. M. M., Ke, M., Silva, S. D., & Levine, A. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4147-9 · Cited by 91
Self-citationChronic Constipation: Current Treatment Options
Liu, L. W. C. (2011) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2011/360463 · Cited by 105
Systematic review of Chinese herbal medicine for functional constipation
Cheng, C. W., Bian, Z., & Wu, T.-X. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4886 · Cited by 89
“This outcome by combining a subjective measure of the completeness of defecation with an objective measure of stool frequency was considered to be clinically meaningful [ 10 ]”
MethodThe PAC ‐ SYM questionnaire for chronic constipation: defining the minimal important difference
Yiannakou, Y., Tack, J. F., Piessevaux, H. H., Dubois, D., Quigley, E. M. M., Ke, M., Silva, S. D., Joseph, A., & Kerstens, R. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14349 · Cited by 92
“The designs of these trials were similar and have been described in detail previously.(11,23-27) In brief, all trials included adults with chronic constipation, defined as ≤2 spontaneous bowel movements per week for >6 months, with hard or very hard stools, a sensation of incomplete evacuation, or straining during def…”
MethodSelf-citationSharma, A., Rao, S. S. C., Kearns, K., Orleck, K. D., & Waldman, S. A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16369 · Cited by 84
Diabetic Enteropathy: From Molecule to Mechanism-Based Treatment
Meldgaard, T., Olesen, S. S., Farmer, A. D., Krogh, K., Wendel, A. A., Brock, B., Drewes, A. M., & Brock, C. (2018) · Journal of Diabetes Research · doi:10.1155/2018/3827301 · Cited by 83
“Novel treatment options include prucalopride [93] that may also improve symptoms of gastroparesis, and linaclotide may be particularly helpful in patients with concomitant symptoms of irritable bowel syndrome [94].”
BackgroundEffect of prucalopride on symptoms of chronic constipation
Tack, J. F., Stanghellini, V., Dubois, D., Joseph, A., Vandeplassche, L. M., & Kerstens, R. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12217 · Cited by 82
Self-citationBarboza, J., Okun, M. S., & Moshiree, B. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1086747 · Cited by 88
“Although prucalopride improves constipation in the general population [42], it may not be an effective option in patients with PD.”
Backgrounddubois, D., Gilet, H., Viala-Danten, M., & Tack, J. F. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01408.x · Cited by 80
Oral Prucalopride in Children With Functional Constipation
Winter, H. S., Lorenzo, C. D., Benninga, M. A., Gilger, M. A., Kearns, G. L., Hyman, P. E., Vandeplassche, L. M., Ausma, J., & Hoppenbrouwers, M. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318292f9ea · Cited by 79
Self-citationGastrointestinal dysmotility disorders in critically ill dogs and cats
Whitehead, K., Cortes, Y., & Eirmann, L. (2016) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12449 · Cited by 91
An update on prucalopride in the treatment of chronic constipation
Omer, A., & Quigley, E. M. M. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17734809 · Cited by 80
Neri, L., Basilisco, G., Corazziari, E. S., Stanghellini, V., Bassotti, G., Bellini, M., Perelli, I., Cuomo, R., & LIRS Study Group (2014) · United European Gastroenterology Journal · doi:10.1177/2050640614528175 · Cited by 85
Gastrointestinal autonomic dysfunction in patients with Parkinson’s disease
Kim, J.-S., & Sung, H.-Y. (2015) · Journal of Movement Disorders · doi:10.14802/jmd.15008 · Cited by 76
Brain‐Gut Axis: From Basic Understanding to Treatment of IBS and Related Disorders
Camilleri, M., & Lorenzo, C. D. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31823d34c3 · Cited by 82
“The agent most thoroughly studied in this group is prucalopride, which accelerated pan-gut and regional transit in patients with chronic constipation (90), relieved symptoms, and was associated with satisfactory symptom relief in patients with severe, chronic constipation who were treated for 12 weeks (91).”
BackgroundSelf-citationGhoshal, U. C., Sachdeva, S., Pratap, N., Verma, A., Karyampudi, A., Misra, A., Abraham, P., Bhatia, S. J., Bhat, N., Chandra, A., et al. (2018) · Indian Journal of Gastroenterology · doi:10.1007/s12664-018-0894-1 · Cited by 80
Pharmacological management of constipation
Emmanuel, A. V., Tack, J. F., Quigley, E. M. M., & Talley, N. J. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01403.x · Cited by 81
Primary Care Management of Chronic Constipation in Asia: The ANMA Chronic Constipation Tool
Gwee, K., Ghoshal, U. C., Gonlachanvit, S., Chua, A. S. B., Myung, S., Rajindrajith, S., Patcharatrakul, T., Choi, M., Wu, J. C., Chen, M., et al. (2013) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2013.19.2.149 · Cited by 84
“od of up to 12 weeks if access to specialized centers is limited, or prucalopride at 2 mg daily for up to 12 weeks.(28,69,74-76) Combining a stimulant or prokinetic agent with an osmotic agent may al-”
BackgroundResultDeMicco, M., Barrow, L., Hickey, B., Shailubhai, K., & Griffin, P. (2017) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x17734697 · Cited by 74
Camilleri, M., & Chang, L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.005 · Cited by 75
Self-citationCinca, R., Chera, D., Gruss, H. ‐., & Halphen, M. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12278 · Cited by 73
Emmanuel, A. V., Cools, M., Vandeplassche, L. M., & Kerstens, R. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.74 · Cited by 73
Self-citationCorsetti, M., Shin, A., Lacy, B. E., Cash, B. D., Simrén, M., Schmulson, M. J., Hou, X., & Lembo, A. J. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.02.003 · Cited by 87
Mendzelevski, B., Ausma, J., CHANTER, D. O., Robinson, P., Kerstens, R., Vandeplassche, L. M., & Camm, A. J. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.04088.x · Cited by 71
Self-citationMedical Management of Constipation in Elderly Patients: Systematic Review
Kang, S. J., Cho, Y. S., Lee, T. H., Kim, S., Ryu, H. S., Kim, J., Park, S., Lee, Y. J., & Shin, J. E. (2021) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm20210 · Cited by 74
“52 In a study that collected all 2484 subjects from 6 RCTs us-ing prucalopride, significantly more patients achieved a mean of ≥ 3 SCBM per week over 12 weeks of treatment in the prucalo - pride group (27.8”
InfluentialClinical utility of colonic manometry in slow transit constipation
Singh, S. M., Heady, S., Coss‐Adame, E., & Rao, S. S. C. (2013) · Neurogastroenterology & Motility · doi:10.1111/nmo.12092 · Cited by 74
Update on constipation: One treatment does not fit all
Foxx–Orenstein, A. E., McNALLY, M. A., & Odunsi, S. T. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.11.813 · Cited by 69
Prokinetics in the Management of Functional Gastrointestinal Disorders
Quigley, E. M. M. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15094 · Cited by 69
Psychotropics, Antidepressants, and Visceral Analgesics in Functional Gastrointestinal Disorders
Törnblom, H., & Drossman, D. A. (2018) · Current Gastroenterology Reports · doi:10.1007/s11894-018-0664-3 · Cited by 73
Review: The treatment of irritable bowel syndrome
Lacy, B. E., Weiser, K., & Lee, R. D. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09104794 · Cited by 85
“Prucalopride is a highly selective 5-HT4 receptor agonist that improves colonic motility, colonic transit and symptoms of constipation in patients with chronic constipation [Camilleri et al. 2008; Emmanuel et al. 2002].”
BackgroundPharmacological treatment for antipsychotic-related constipation
Every‐Palmer, S., Newton‐Howes, G., & Clarke, M. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011128.pub2 · Cited by 78
Prucalopride: safety, efficacy and potential applications
Quigley, E. M. M. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11423706 · Cited by 77
“Where reported, the prevalence of serious adverse events was similar for placebo and prucalopride [Tack et al. 2009; Quigley et al. 2009; Camilleri et al. 2008b].”
BackgroundResultInfluentialKeller, J., Wedel, T., Seidl, H., Kreis, M. E., Andresen, V., Preiß, J., Layer, P., & van der Voort, I. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0029-1245993 · Cited by 73
Management of faecal incontinence and constipation in adults with central neurological diseases
Coggrave, M., & Norton, C. S. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002115.pub4 · Cited by 74
Ding, C., Fan, W., Gu, L., Tian, H., Ge, X., Gong, J., Nie, Y., & Li, N. (2018) · Gastroenterology report · doi:10.1093/gastro/gox036 · Cited by 65
Metadata
- Authors
- Camilleri, M., Kerstens, R., Rykx, A., & Vandeplassche, L.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Camilleri, Michael
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-29
- Volume
- 358
- Issue
- 22
- Pages
- 2344-2354
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2068454300
- Cited by
- 576
- References
- 36
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 28 · 2020: 28 · 2019: 19 · 2018: 29 · 2017: 33 · 2016: 38 · 2015: 33 · 2014: 46 · 2013: 50 · 2012: 49
- FWCI
- 45.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- prucalopride, serotonin receptor agonists, 5-HT4 receptor agonist, stool frequency, treatment-related adverse events, cardiovascular safety
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Benzofurans, Chronic Disease, Constipation, Defecation, Double-Blind Method, Electrocardiography, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Serotonin Receptor Agonists, Laxatives, Serotonin 5-HT4 Receptor Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.